P/E at 37.22 vs Industry's 36.85: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Premium Reflecting Sector Confidence

The current P/E of 37.22 for Sun Pharmaceutical Industries Ltd represents a modest premium of approximately 1% over the industry average of 36.85. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, potentially reflecting confidence in its earnings stability or growth prospects. However, the premium is not excessive, indicating that valuation remains broadly in line with sector norms. This contrasts with some large-cap pharmaceuticals that trade at multiples significantly above industry averages, signalling either overvaluation or exceptional growth expectations.

Given the sector’s mixed recent results—7 positive, 4 flat, and 1 negative out of 12 stocks reporting—this valuation premium may be justified by Sun Pharma’s relative resilience. Yet, Sun Pharmaceutical Industries Ltd’s P/E ratio remains close enough to the sector average to invite questions about whether the premium is sustainable or vulnerable to sector headwinds. Sun Pharma’s valuation thus sits at a delicate balance point, where shifts in earnings or market sentiment could quickly alter investor perception — what is the current rating?

Performance Across Timeframes: Strong Long-Term Gains Amid Recent Volatility

Examining Sun Pharmaceutical Industries Ltd’s returns reveals a compelling divergence between short- and long-term performance. Over one year, the stock has gained 19.36%, significantly outperforming the Sensex’s 2.23% loss. The year-to-date return of 13.28% also contrasts with the Sensex’s 7.40% decline, underscoring the stock’s relative strength in a challenging market environment.

However, the short-term picture is less favourable. The stock has declined 2.09% over the past week and is down 0.60% on the day, while the Sensex gained 1.62% and 0.62% respectively in the same periods. Despite a 3-month gain of 7.00% outperforming the Sensex’s 2.46%, the recent weekly and daily losses suggest some profit-taking or short-term pressure. This raises the question of whether the recent weakness is a temporary correction or the start of a more sustained pullback — is this a recovery or a dead-cat bounce?

Moving Average Configuration: Mixed Signals from Technical Indicators

The technical setup for Sun Pharmaceutical Industries Ltd offers further insight into its recent price action. The stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive medium- to long-term trend. However, it remains below its 5-day moving average, signalling short-term hesitation or consolidation.

This configuration suggests that while the stock has maintained a solid base over recent months, the immediate momentum has softened. The fact that it is close to its 52-week high—just 4.05% away from Rs 2047.55—reinforces the idea that the stock is in a mature phase of its rally, where short-term fluctuations are more pronounced. The 2-day consecutive gain of 0.92% indicates some recent buying interest, but the inability to sustain above the 5-day average points to caution among traders. Is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed Results

The Pharmaceuticals & Biotechnology sector has delivered a mixed bag of results recently, with 7 stocks reporting positive outcomes, 4 flat, and 1 negative. This uneven performance reflects ongoing challenges and opportunities within the sector, including regulatory pressures, patent expiries, and innovation cycles. Against this backdrop, Sun Pharmaceutical Industries Ltd’s ability to maintain a valuation premium and deliver solid long-term returns is notable.

Its market capitalisation of approximately ₹4,67,438.44 crores places it firmly in the large-cap category, underscoring its significance within the sector. The stock’s performance relative to the sector and Sensex highlights its role as a bellwether, though the recent short-term volatility suggests investors are weighing sector headwinds carefully. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

On 8 June 2026, Sun Pharmaceutical Industries Ltd’s rating was updated from Hold, reflecting a reassessment of its fundamentals and market position. While the current rating is not disclosed, the change indicates a shift in the evaluation of the stock’s prospects based on the latest data. The Mojo Score of 74.0 supports a generally favourable view, consistent with its valuation and performance metrics.

This reassessment comes amid a backdrop of strong long-term returns—71.07% over three years and 147.91% over five years—both comfortably ahead of the Sensex’s 20.07% and 44.82% respectively. However, the 10-year return of 131.28% trails the Sensex’s 181.05%, suggesting that while the stock has been a strong performer in recent years, it has lagged over the longer term. This nuanced rating update invites further scrutiny of the stock’s current positioning — what is the current rating?

Conclusion: A Balanced Valuation with Mixed Momentum Signals

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight premium to its sector, supported by strong long-term returns and a solid market capitalisation. The valuation premium is modest, reflecting investor confidence without excessive exuberance. Performance over the past year and longer periods has been robust, significantly outperforming the Sensex, though recent short-term weakness and mixed moving average signals suggest caution.

The sector’s mixed results and the stock’s recent rating reassessment from Hold add further complexity to the investment case. The technical configuration, with the stock above most moving averages but below the 5-day average, indicates a pause in momentum rather than a clear trend reversal. This nuanced data invites investors to consider carefully the balance between valuation, performance, and technical signals — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today